[A18-46] Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15
Last updated 16.08.2018
Project no.:A18-46
Commission:
Commission awarded on 09.07.2018 by the Federal Joint Committee (G-BA).Report type:
AddendumStatus:Commission completed
Department/Division:
Drug AssessmentTopic:
Airways and respiratory system
Indication:
Adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2 agonist
Result of dossier assessment:
Conclusion of dossier assessment A18-15 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Federal Joint Committee (G-BA)
2018-08-16 A G-BA decision was published.